Emerging links between pediatric lysosomal storage diseases and adult parkinsonism
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Lysosomal storage disorders comprise a clinically heterogeneous group of autosomal‐recessive or X‐linked genetic syndromes caused by disruption of lysosomal biogenesis or function resulting in accumulation of nondegraded substrates. Although lysosomal storage disorders are diagnosed predominantly in children, many show variable expressivity with clinical presentations possible later in life. Given the important role of lysosomes in neuronal homeostasis, neurological manifestations, including movement disorders, can accompany many lysosomal storage disorders. Over the last decade, evidence from genetics, clinical epidemiology, cell biology, and biochemistry have converged to implicate links between lysosomal storage disorders and adult‐onset movement disorders. The strongest evidence comes from mutations in Glucocerebrosidase , which cause Gaucher's disease and are among the most common and potent risk factors for PD. However, recently, many additional lysosomal storage disorder genes have been similarly implicated, including SMPD1 , ATP13A2 , GALC , and others. Examination of these links can offer insight into pathogenesis of PD and guide development of new therapeutic strategies. We systematically review the emerging genetic links between lysosomal storage disorders and PD. © 2019 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic effects on gene expression across human tissues
GTEx Consortium (2017) · Nature · doi:10.1038/nature24277 · Cited by 4,036
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135 · cited 2×
“Heterozygous mutations in the GBA1 gene are the most common genetic risk factor for PD with a predicted frequency of 7% to 10% in the PD population.(12) This is an example of genetic pleiotropy, by which variation in a single gene (GBA1) can influence multiple, distinct clinical phenotypes (GD and PD), through autosom…”
BackgroundResultRamirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112 · cited 1×
“In a large genome-wide association study (GWAS) meta-analysis, variants at the GALC locus were significantly associated with PD risk.(72) The causal variant for the association of GALC locus with PD risk remains to be defined.”
BackgroundDopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Self-citationHsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology
Kirkegaard, T., Roth, A. G., Petersen, N. H. T., Mahalka, A. K., Olsen, O. D., Moilanen, I., Zylicz, A., Knudsen, J., Sandhoff, K., Arenz, C., et al. (2010) · Nature · doi:10.1038/nature08710 · Cited by 519 · cited 1×
“As a result, patients display accumulation of the ASM substrate sphingomyelin, as well as bis(monoacylglycero) phosphate and lysosphingomyelin within the lysosome.(33,34) Under stress conditions, ASM is also translocated from the lysosome to the outer leaflet of the plasmamembrane, where sphingomyelin hydrolysis leads…”
BackgroundExcessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433 · cited 2×
“Indeed, among 3,000 PD cases and controls with exome sequencing data, we discovered a significant “burden” of putative damaging variants among this LSD gene set.(116) This result was robust to the exclusion of GBA1 and was consistent in two independent data sets, suggesting that other LSD genes besides GBA1 likely con…”
BackgroundResultSelf-citationBis, J. C., Jian, X., Kunkle, B. W., Chen, Y., Hamilton-Nelson, K. L., Bush, W. S., Salerno, W. J., Lancour, D., Ma, Y., Renton, A. E., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0112-7 · Cited by 248
Autophagic/lysosomal dysfunction in Alzheimer’s disease
Orr, M. E., & Oddo, S. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt217 · Cited by 199
The role of ATP13A2 in Parkinson’s disease: clinical phenotypes and molecular mechanisms
Park, J., Blair, N. F., & Sue, C. M. (2015) · Movement Disorders · doi:10.1002/mds.26243 · Cited by 173
Cited by
GBA, Gaucher Disease, and Parkinson’s Disease: From Genetic to Clinic to New Therapeutic Approaches
Riboldi, G. M., & Di Fonzo, A. B. (2019) · Cells · doi:10.3390/cells8040364 · Cited by 274
“This is the case for a number of LSD in the context of PD or of a parkinsonian degeneration, such as SMPD1 (sphingomyelin phosphodiesterase, Niemann–Pick disease), ATP13A2 (P5-type ATPase, Kufor–Rakeb disease), GALC (galactosylceramidase, Krabbe disease), NPC1 (Niemann–Pick type C), NAGLU (α-N-acetylglucosminidase, Sa…”
BackgroundInflammatory bowel disease and Parkinson’s disease: common pathophysiological links
Lee, H.-S., Lobbestael, E., Vermeire, S., Sabino, J., & Cleynen, I. (2021) · Gut · doi:10.1136/gutjnl-2020-322429 · Cited by 151
Variants in saposin D domain of prosaposin gene linked to Parkinson’s disease
Oji, Y., Hatano, T., Ueno, S.-I., Funayama, M., Ishikawa, K.-I., Okuzumi, A., Noda, S., Sato, S., Satake, W., Toda, T., et al. (2020) · Brain · doi:10.1093/brain/awaa064 · Cited by 116
Ye, H., Ojelade, S. A., Li-Kroeger, D., Zuo, Z., Wang, L., Li, Y., Gu, J. Y., Tepass, U., Rodal, A. A., Bellen, H. J., et al. (2020) · eLife · doi:10.7554/elife.51977 · Cited by 51
Self-citationHermey, G., & Klein, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.361544 · Cited by 10
“Congruously, a number of strategies targeting the GCase ceramide metabolism to improve autophagy-lysosome dynamics have been suggested to be therapeutic for both GD and PD (Bonam et al., 2019; Ysselstein et al., 2019).”
Background
Metadata
- Authors
- Ysselstein, D., Shulman, J. M., & Krainc, D.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2019-02-06
- Volume
- 34
- Issue
- 5
- Pages
- 614-624
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2913039512
- Cited by
- 40
- References
- 12
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.